NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
Clinical Trials
107 trialsNCT01165346 2026-03-13
CKNO-HEP
Centre Oscar Lambret
Phase 2 Completed
NCT04567615 2026-01-08
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
Bristol-Myers Squibb
Phase 2 Completed
NCT05532319 2025-12-30
FRONT-1
Guangxi Medical University
Phase 2 Completed
NCT00183885 2025-10-30
A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma
University of Southern California
Phase 2 Completed
NCT04264260 2025-09-08
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 2 Completed
NCT03037437 2025-09-04
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01356628 2025-07-28
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Thomas Jefferson University
Phase 2 Completed
NCT02185768 2025-07-04
IDASPHERE II
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT00410956 2024-12-10
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02431676 2024-08-28
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04518852 2024-06-25
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Sichuan Cancer Hospital and Research Institute
Phase 2 Completed
NCT03817736 2024-05-09
START-FIT
The University of Hong Kong
Phase 2 Completed
NCT03230318 2023-12-19
FIDES-01
Basilea Pharmaceutica
Phase 2 Completed
NCT00539643 2023-08-18
Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00095992 2023-08-04
SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT03572582 2023-07-20
IMMUTACE
AIO-Studien-gGmbH
Phase 2 Completed
NCT00003907 2023-07-05
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00813293 2023-06-13
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT00587067 2023-04-04
A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02821754 2023-03-28
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05471674 2023-02-01
Neoadjuvant Anti-PD1 in HCC
The University of Hong Kong
Phase 2 Completed
NCT00956930 2022-11-21
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
Northwestern University
Phase 2 Completed
NCT01180959 2022-11-07
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02141906 2022-08-18
A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT03111732 2021-12-03
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00335829 2021-08-13
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Yale University
Phase 2 Completed
NCT01033240 2021-04-08
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Daiichi Sankyo
Phase 2 Completed
NCT01967823 2021-03-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01636284 2021-01-20
FLASH
SillaJen, Inc.
Phase 2 Completed
NCT03380130 2020-11-04
NASIR-HCC
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Completed
NCT00049322 2020-09-01
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01775501 2020-04-22
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT01877187 2020-04-15
Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
Yale University
Phase 2 Completed
NCT00717756 2020-02-17
Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Brown University
Phase 2 Completed
NCT01334112 2019-12-12
AXITINIB
University Health Network, Toronto
Phase 2 Completed
NCT00941967 2019-07-10
Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Completed
NCT01005199 2019-05-15
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
Swiss Cancer Institute
Phase 2 Completed
NCT02471313 2019-04-23
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01743469 2019-01-08
A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
Ipsen
Phase 2 Completed
NCT00004136 2018-11-06
Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00019474 2018-09-14
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
Montefiore Medical Center
Phase 2 Completed
NCT02006030 2018-09-04
TACE
Polaris Group
Phase 2 Completed
NCT00906373 2018-06-04
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
Eli Lilly and Company
Phase 2 Completed
NCT00047229 2017-11-08
Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
University Health Network, Toronto
Phase 2 Completed
NCT00881751 2017-09-11
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Medical University of South Carolina
Phase 2 Completed
NCT01177007 2017-08-28
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Yale University
Phase 2 Completed
NCT01375569 2017-07-28
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00483405 2017-07-12
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed